



Atty. Dkt. No. 018733-0884

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JAN 17 2003
TECH CENTER 1600/2900

Applicant: Hans J. HANSEN *et al.*

Title: USE OF BI-SPECIFIC
ANTIBODIES FOR PRE-
TARGETING DIAGNOSIS AND
THERAPY

Appl. No.: 09/337,756

Filing Date: 06/22/1999

Examiner: D. Saunders

Art Unit: 1644

AMENDMENT TRANSMITTAL

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

☒ Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.

☐ Small Entity statement is enclosed.

☒ The fee required for additional claims is calculated below:

	Claims as Amended		Previously Paid For		Extra Claims Present		Rate		Additional Claims Fee
Total Claims:	14	—	14	=	0	x	\$18.00	=	\$0.00
Independents:	2	—	2	=	0	x	\$84.00	=	\$0.00
First presentation of any Multiple Dependent Claims:						+	\$280.00	=	\$0.00
CLAIMS FEE TOTAL:									\$0.00

☒ Applicants hereby petition for an extension of time under 37 C.F.R. § 1.136(a) for the total number of months checked below:

<input type="checkbox"/>	Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the second month:	\$410.00	\$0.00
			\$930.00
<input checked="" type="checkbox"/>	Extension for response filed within the third month:	\$930.00	(\$55.00 paid 11/25/02)
<input type="checkbox"/>	Extension for response filed within the fourth month:	\$1,450.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fifth month:	\$1,970.00	\$0.00
	EXTENSION FEE TOTAL:		\$820.00
	CLAIMS AND EXTENSION FEE TOTAL:		\$820.00
<input checked="" type="checkbox"/>	Small Entity Fees Apply (subtract ½ of above):		\$410.00
	TOTAL FEE:		\$410.00

- ☐ Please charge Deposit Account No. 19-0741 in the amount of \$0.00. A duplicate copy of this transmittal is enclosed.
- ☒ A check in the amount of \$410.00 is enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date January 14, 2003

By Barbara A. McDowell

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

Barbara A. McDowell
Attorney for Applicants
Registration No. 31,640



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

29/C
N/E
RECEIVED
JAN 17 2003
TECH CENTER 1600/2900

In re patent application of

Hans J. HANSEN *et al.*

Group Art Unit: 1644

Serial No. 09/337,756

Examiner: D. Saunders

Filed: June 22, 1999

For: USE OF BI-SPECIFIC ANTIBODIES FOR PRE-TARGETING
DIAGNOSIS AND THERAPY

AMENDMENT AND REQUEST FOR RECONSIDERATION
UNDER 37 C.F.R. §1.116

Assistant Commissioner for Patents
Washington, D.C. 20231

BOX AF

Sir:

This communication is responsive to the Advisory Action mailed in the above-captioned case on January 2, 2002. Petition is hereby made for second and third month extensions of time up to and including January 25, 2003. A check is attached in full payment of all fees believed to be due in connection with submission of this paper. If the amount is incorrect, however, the Commissioner is authorized to make appropriate charges or credits to Deposit Account No. 19-0741 to provide exact payment.

Reconsideration and reexamination of the application in light of the amendments and remarks herein set forth is respectfully requested.

IN THE CLAIMS:

Please enter the following amended versions of claims 53 and 54 into the record.

53. (Amended) The method of claim 1, further comprising, when said first targetable conjugate additionally comprises a prodrug, administering a second targetable conjugate which comprises a carrier portion which comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment, and an enzyme capable of converting said prodrug to a drug or of reconverting a detoxified intermediate of said drug to a toxic form.

*This amended
assembly
is entered*